Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Telemedicine takes on lymphoma: a 350-Patient trial

NCT ID NCT03336138

Knowledge-focused Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether using telemedicine (remote doctor visits) can improve how aggressive lymphomas are managed. The main goal was to see if patients got the right amount of chemotherapy on time. 350 patients from 10 hospitals took part. The study compared telemedicine support to usual care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

350 people

The number who actually took part.

Started

Jan 2012

Finished

Jan 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with a recent diffuse large B cell lymphoma (LBDGC), histologically proven, with treatment not started * a priori likely to be treated by rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP21) for 8 cycles or rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP). * Index international prognosis (IPI) measurable (IPI-aa), adjusted for age. Any IPI-aa is eligible. * accepting the study Exclusion Criteria: * Patient with another type of lymphoma (including transformed follicular forms) * Patient having already started his treatment. * Life expectancy \<3 months. * Carcinologic history * Serum positive for HIV or hepatitis B virus (HBV).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffuse large B cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphoma

Contacts and locations

Locations

  • Bayonne Hospital

    Bayonne, 64000, France

  • Clinique Claude Bernard

    Albi, 81000, France

  • Clinique Marzet

    Pau, 64000, France

  • Clinique Saint Jean

    Toulouse, 31000, France

  • Hospital

    Auch, 32000, France

  • Hospital

    Montauban, 82000, France

  • Rodez Hospital

    Rodez, 12000, France

  • Tarbes Hospital

    Tarbes, 65000, France

  • University Hospital Bordeaux

    Bordeaux, 33000, France

  • University Hospital of Toulouse

    Toulouse, France, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.